NCT00533364View on ClinicalTrials.gov

Effect of SBG in Patients With Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

January 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

SBG (Soluble beta-glucan)

Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.

Trial Locations (2)

6026

Ålesund Hospital, Ålesund

0407

Ullevål University Hospital, Oslo

Sponsors
All Listed Sponsors
lead

Biotec Pharmacon ASA

INDUSTRY

NCT00533364 - Effect of SBG in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter